Overview

the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and PK of KX-826 following topical multiple ascending dose administration.
Phase:
Phase 1
Details
Lead Sponsor:
Suzhou Kintor Pharmaceutical Inc,